Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Intrust Bank NA

Intrust Bank NA lowered its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 7.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,292 shares of the medical equipment provider’s stock after selling 355 shares during the period. Intrust Bank NA’s holdings in Lantheus were worth $384,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Wilmington Savings Fund Society FSB purchased a new stake in Lantheus during the 3rd quarter worth $25,000. Kestra Investment Management LLC purchased a new stake in shares of Lantheus in the fourth quarter worth about $27,000. UMB Bank n.a. grew its stake in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 134 shares in the last quarter. World Investment Advisors LLC purchased a new stake in shares of Lantheus during the 3rd quarter valued at about $60,000. Finally, Parkside Financial Bank & Trust lifted its position in Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock worth $76,000 after acquiring an additional 280 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of LNTH stock opened at $96.16 on Monday. The firm has a fifty day moving average of $93.21 and a two-hundred day moving average of $96.38. The firm has a market cap of $6.59 billion, a P/E ratio of 16.00 and a beta of 0.38. Lantheus Holdings, Inc. has a 1-year low of $58.16 and a 1-year high of $126.89.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. On average, sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Activity

In other news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

LNTH has been the subject of several recent research reports. Truist Financial increased their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. B. Riley dropped their price target on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. JMP Securities reissued a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Finally, The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price for the company. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.